ATE477812T1 - Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit - Google Patents

Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit

Info

Publication number
ATE477812T1
ATE477812T1 AT03705492T AT03705492T ATE477812T1 AT E477812 T1 ATE477812 T1 AT E477812T1 AT 03705492 T AT03705492 T AT 03705492T AT 03705492 T AT03705492 T AT 03705492T AT E477812 T1 ATE477812 T1 AT E477812T1
Authority
AT
Austria
Prior art keywords
obesity
whey protein
tryptophan
protein hydrolysates
rich peptides
Prior art date
Application number
AT03705492T
Other languages
English (en)
Inventor
Marjoleine Maria Theodora Gerarda Bartels-Arntz
Johannes Steijns
Petronella Caessens
Original Assignee
Campina Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32844952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE477812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Campina Bv filed Critical Campina Bv
Application granted granted Critical
Publication of ATE477812T1 publication Critical patent/ATE477812T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03705492T 2003-02-07 2003-02-07 Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit ATE477812T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2003/000084 WO2004069265A1 (en) 2003-02-07 2003-02-07 Use of tryptophan rich peptides

Publications (1)

Publication Number Publication Date
ATE477812T1 true ATE477812T1 (de) 2010-09-15

Family

ID=32844952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705492T ATE477812T1 (de) 2003-02-07 2003-02-07 Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit

Country Status (9)

Country Link
US (2) US7582601B2 (de)
EP (1) EP1599215B1 (de)
JP (1) JP4611752B2 (de)
AT (1) ATE477812T1 (de)
AU (1) AU2003207417A1 (de)
DE (1) DE60333868D1 (de)
DK (1) DK1599215T3 (de)
ES (1) ES2350310T3 (de)
WO (1) WO2004069265A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538704A (ja) * 2002-07-01 2005-12-22 ユニリーバー・ナームローゼ・ベンノートシヤープ 満腹誘導組成物
EP1753443A1 (de) * 2004-05-27 2007-02-21 Campina Nederland Holding B.V. Verwendung von proteinhydrolysaten zur herstellung eines medikaments zur prophylaxe und/oder behandlung einer dpp-iv-vermittelten erkrankung
DE102004040452A1 (de) * 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR101331777B1 (ko) 2004-12-23 2013-11-21 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ-ｉｖ를 억제하는 펩타이드가 풍부한 단백질가수분해물 및 이의 용도
CN101212911B (zh) * 2005-07-01 2012-12-05 努特里希亚公司 含水解的蛋白质的婴儿营养品
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
ES2382910T3 (es) 2006-11-02 2012-06-14 Dsm Ip Assets B.V. Uso de hidrolizados de lisozima que contienen triptófano
US7989007B2 (en) * 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
KR20100044204A (ko) 2007-07-06 2010-04-29 디에스엠 아이피 어셋츠 비.브이. 식품 조성물
CN102076222B (zh) * 2008-04-29 2014-04-09 帝斯曼知识产权资产管理有限公司 包含碳水化合物和含色氨酸的肽的组合物
EP2318021A4 (de) * 2008-06-26 2012-10-31 Healthlinx Ltd Protokolle zur behandlung und prävention von fettsucht und daraus entstehenden komplikationen
JP5735734B2 (ja) * 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
CN103153326B (zh) * 2010-10-05 2015-08-19 帝斯曼知识产权资产管理有限公司 含有色氨酸的肽
PL2701716T3 (pl) 2011-04-28 2018-02-28 Dsm Ip Assets B.V. Hydrolizaty białkowe jako środki do przezwyciężania uzależnień
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
EP3082465A2 (de) * 2013-12-19 2016-10-26 Abbott Laboratories Nährstoffzusammensetzung mit hydrolisiertem protein
CN107404922B (zh) 2015-03-30 2021-09-14 雀巢产品有限公司 乳基蛋白质水解物及由其制备的组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8523338D0 (en) * 1985-09-20 1985-10-23 Kreitzman S N Treatment of obesity
US6013622A (en) 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US6838431B2 (en) * 1999-07-27 2005-01-04 Pacific Health Laboratories, Inc. Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety
KR100796853B1 (ko) * 2000-12-06 2008-01-22 캄피나 쥐벨 베.붸. 과량 트립토판 함유 펩티드의 제조방법
US6429190B1 (en) * 2000-12-15 2002-08-06 Pacifichealth Laboratories, Inc. Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)

Also Published As

Publication number Publication date
EP1599215B1 (de) 2010-08-18
JP4611752B2 (ja) 2011-01-12
US7582601B2 (en) 2009-09-01
US20060257497A1 (en) 2006-11-16
JP2006514083A (ja) 2006-04-27
WO2004069265A1 (en) 2004-08-19
DK1599215T3 (da) 2010-11-15
ES2350310T3 (es) 2011-01-21
EP1599215A1 (de) 2005-11-30
US20100087359A1 (en) 2010-04-08
DE60333868D1 (de) 2010-09-30
AU2003207417A1 (en) 2004-08-30

Similar Documents

Publication Publication Date Title
ATE477812T1 (de) Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
UG et al. Antihypertensive activity of fish protein hydrolysates and its peptides
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DE60305055D1 (de) Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten
DE602004023210D1 (de) Biologisch nicht-abbaubares peptid, inhibitor des angiotensinumwandelnden enzyms, arzneimittel und funktionelles nahrungsmittel
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
KR20030025907A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE602005026014D1 (de) Proteinartige verbindungen und anwendungen davon
ATE349538T1 (de) Collectin-komplement aktivierende proteinchimären
ATE386104T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DK0838473T3 (da) Peptid til inhibering af blodtriglyceridkoncentrationsstigning og inhibitor for blodtriglycerid-koncentrationsstigning omfattende peptidet som aktiv bestanddel
ATE388166T1 (de) Bioaktive peptide, die durch enzymatische hydrolyse aus den proteinen von eiweiss gewonnen werden
EP4225382A4 (de) Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
KR960701089A (ko) 지방세포 분화 억제 펩타이드 및 그를 유효성분으로 포함하는 지방세포 분화 억제제
ATE526023T1 (de) Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DE60030787D1 (de) Verwendung von l-carnitin als stabilitsator für proteine
WO2005023896A3 (en) Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
JP2001213792A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1599215

Country of ref document: EP